论文部分内容阅读
用重组干扰素α２ｂ３×１０６ＩＵ联合病毒唑治疗８７例肾综合征出血热患者，并与单用病毒唑组７１例进行了疗效对比．结果，联合治疗组在缩短少尿期、血小板和尿素氮异常天数方面优于单用病毒唑治疗组（Ｐ＜０．０５），病死率明显低于单用组（Ｐ＜０．０１），少尿期越期率明显高（Ｐ＜０．０１），并发症中心肌炎、腔道大出血等明显少．提示肾综合征出血热病人早期用重组干扰素联合病毒唑对缩短病程、减少病死率有明显作用．
87 patients with hemorrhagic fever with renal syndrome were treated with recombinant interferon α 2b virus and ribavirin and compared with 71 patients treated with ribavirin alone. The results showed that the combined treatment group was superior to ribavirin alone group in reducing the number of days with oliguria, platelets and urea nitrogen (P <0.05), and the mortality rate was significantly lower in the combined treatment group than in the control group (P <0.01) Hyperuricemia period was significantly higher (P <0.01), complications of myocarditis, haemorrhage and other obvious less. Prompt patients with renal syndrome hemorrhagic fever with recombinant interferon early ribavirin to shorten the course of the disease, reduce the mortality significant role.